It is well past time to stop this negative BS concerning Replicel.

[gmonasco]

Anyone who can read that news release and come away thinking that efficacy was a minor issue in this trial, either needs glasses or some reading comprehension courses.

Most people with ordinary reading comprehension skills can understand that the word "if" is a conditional and doesn't promise anything.

And, of course, my original point was not that demonstrating safety was vastly, vastly more important than demonstrating efficacy, but that the nature of the trial, as in all phase I trials, was skewed very heavily towards testing safety and not efficacy. Sure, the efficacy results were not encouraging, but neither was the trial anything close to being a full-blown test of efficacy.